Details
Description
In these analyses, we aimed to describe the utilization of selected non-insulin antidiabetics in the TriNetX Live™ platform. We examined 20 non-insulin antidiabetics, including albiglutide, alogliptin, bexagliflozin, canagliflozin, dapagliflozin, dulaglutide, empagliflozin, ertugliflozin, exenatide, glimepiride, glipizide, glyburide, linagliptin, liraglutide, lixisenatide, metformin, saxagliptin, semaglutide, sitagliptin, and tirzepatide. The study period includes data from October 1, 2017 to September 30, 2023.
- Analysis 1: We ran this query on January 25, 2024. This query contains data from 81 health care organizations (HCOs) provided through the TriNetX Live™ platform in their USA Network, which includes HCOs that may implement date shifting between 0 and 365 days in either direction.
- Analysis 2: We ran this query on April 17, 2024. This query contains data from 60 HCOs provided through the TriNetX Live™ platform in their USA Network Minimal Shift, which includes HCOs that may implement date shifting between 0 and 14 days in either direction. This includes all HCOs from the USA Network without date shifting.